Skip to main navigation Skip to search Skip to main content

A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data

  • Alaa Rahhal
  • , Mostafa Najim
  • , Asad Abusweireh
  • , Masa Habra
  • , Lenah Elgassim
  • , Mohammed Omer Ali
  • , Mhd Baraa Habib
  • , Raad Tahtouh
  • , Mohammad Al-Awad
  • , Amer Hussien Aljundi
  • , Ahmed Mahfouz
  • , Mohammed Thamer Ali
  • , Wafer Dabdoob
  • , Sumaya Alyafei
  • , Nidal Asaad

Research output: Contribution to journalReview articlepeer-review

Abstract

Sodium glucose cotransporter-2 (SGLT2) inhibitors and loop diuretics can cause volume depletion. However, the long-term safety of the concurrent use of both agents has not been widely evaluated. We conducted a retrospective observational cohort study to evaluate the safety of SGLT2 inhibitors with loop diuretics vs SGLT2 inhibitors alone among diabetic patients. The primary endpoint was a composite of volume-depletion adverse events at 1 month and 12 months. Of the 400 patients included, 98 received SGLT2 inhibitors with a loop diuretic and 302 received SGLT2 inhibitors alone. The concurrent use of SGLT2 inhibitors and loop diuretics was tolerated at 1 month; however, it resulted in a significant increase in volume-depletion events at 12 months (10.2% vs 1.7%; aHR = 7.03, 95% CI (1.80-27.37), P-value = 0.005). In conclusion, the long-term concurrent use of SGLT2 inhibitors and loop diuretics increases the risk of volume depletion, warranting frequent monitoring.

Original languageEnglish (US)
Article number100995
JournalCurrent Problems in Cardiology
Volume47
Issue number10
DOIs
StatePublished - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data'. Together they form a unique fingerprint.

Cite this